Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

182 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Perspectives of drug-eluting stents: the next revolution.
Moses JW, Kipshidze N, Leon MB. Moses JW, et al. Among authors: kipshidze n. Am J Cardiovasc Drugs. 2002;2(3):163-72. doi: 10.2165/00129784-200202030-00004. Am J Cardiovasc Drugs. 2002. PMID: 14727979 Review.
Update on sirolimus drug-eluting stents.
Kipshidze N, Leon MB, Tsapenko M, Falotico R, Kopia GA, Moses J. Kipshidze N, et al. Curr Pharm Des. 2004;10(4):337-48. doi: 10.2174/1381612043453315. Curr Pharm Des. 2004. PMID: 14965195 Review.
Systemic targeted delivery of antisense with perflourobutane gas microbubble carrier reduced neointimal formation in the porcine coronary restenosis model.
Kipshidze NN, Porter TR, Dangas G, Yazdi H, Tio F, Xie F, Hellinga D, Fournadjiev J, Wolfram R, Seabron R, Waksman R, Abizaid A, Roubin G, Iyer S, Leon MB, Moses JW, Iversen P. Kipshidze NN, et al. Cardiovasc Radiat Med. 2003 Jul-Sep;4(3):152-9. doi: 10.1016/S1522-1865(03)00184-7. Cardiovasc Radiat Med. 2003. PMID: 14984716
Advanced c-myc antisense (AVI-4126)-eluting phosphorylcholine-coated stent implantation is associated with complete vascular healing and reduced neointimal formation in the porcine coronary restenosis model.
Kipshidze NN, Iversen P, Kim HS, Yiazdi H, Dangas G, Seaborn R, New G, Tio F, Waksman R, Mehran R, Tsapenko M, Stone GW, Roubin GS, Iyer S, Leon MB, Moses JW. Kipshidze NN, et al. Catheter Cardiovasc Interv. 2004 Apr;61(4):518-27. doi: 10.1002/ccd.20007. Catheter Cardiovasc Interv. 2004. PMID: 15065150
Novel site-specific systemic delivery of Rapamycin with perfluorobutane gas microbubble carrier reduced neointimal formation in a porcine coronary restenosis model.
Kipshidze NN, Porter TR, Dangas G, Yazdi H, Tio F, Xie F, Hellinga D, Wolfram R, Seabron R, Waksman R, Abizaid A, Roubin G, Iyer S, Colombo A, Leon MB, Moses JW, Iversen P. Kipshidze NN, et al. Catheter Cardiovasc Interv. 2005 Mar;64(3):389-94. doi: 10.1002/ccd.20285. Catheter Cardiovasc Interv. 2005. PMID: 15736246
Update on drug-eluting coronary stents.
Kipshidze NN, Tsapenko MV, Leon MB, Stone GW, Moses JW. Kipshidze NN, et al. Expert Rev Cardiovasc Ther. 2005 Sep;3(5):953-68. doi: 10.1586/14779072.3.5.953. Expert Rev Cardiovasc Ther. 2005. PMID: 16181039 Review.
Complete vascular healing and sustained suppression of neointimal thickening after local delivery of advanced c-myc antisense at six months follow-up in a rabbit balloon injury model.
Kipshidze N, Iversen P, Keane E, Stein D, Chawla P, Skrinska V, Shankar LR, Mehran R, Chekanov V, Dangas G, Komorowski R, Haudenschild C, Khanna A, Leon M, Keelan MH, Moses J. Kipshidze N, et al. Cardiovasc Radiat Med. 2002 Jan-Mar;3(1):26-30. doi: 10.1016/s1522-1865(02)00149-x. Cardiovasc Radiat Med. 2002. PMID: 12479913
182 results